×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Skin Cancer

Jason M. Broderick
The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor. 
Brielle Urciuoli
Recent research, conducted at NYU Langone Health and presented at the Oncology Nursing Society (ONS) Annual Congress, sought to find out how patients with melanoma perceived skin health education, and their willingness be involved in their own surveillance or a loved one’s.
Barbara Tako
One melanoma survivor offers advice for Skin Cancer Awareness Month.
Kate Beland
I think being an athlete is what saved my life.
Nicholas Esposito
If I ever got sick or injured I would go to the children’s hospital, but that was nothing like a real hospital where people are fighting for their life day-in and day-out. I absolutely hated it, and still do. I was in Emory Hospital visiting my dad two to three times a week for about six months, and every time I walked in that place, it just gave me the heebie-jeebies.
Katie Kosko and Brielle Urciuoli
Mike Schmidt developed stage 3 melanoma after years of playing professional baseball for the Philadelphia Phillies.
Felicia Mitchell
After radiation, as the skin heals, a compassionate dermatologist can help us to monitor any lingering side-effects.
Jason M. Broderick
The combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted Food and Drug Administration (FDA) approval for the treatment of patients with BRAF V600E– or V600K–positive stage 3 melanoma following complete resection.
Jason M. Broderick
The Food and Drug Administration (FDA) granted a priority review to a biologics license application (BLA) for an immunotherapy agent – cemiplimab – to be used to treat metastatic cutaneous squamous cell carcinoma (a type of skin cancer; CSCC) or patients with locally advanced CSCC who are not eligible for surgery.
Tamera Anderson-Hanna
May is skin cancer awareness month, and a good reminder to schedule an appointment with your dermatologist.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable